Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Effectiveness and Influencing Factors of Percutaneous Transluminal Angioplasty for Stenosis of Transposed Brachiobasilic Arteriovenous Fistula

´ëÇÑ¿µ»óÀÇÇÐȸÁö 2019³â 80±Ç 3È£ p.477 ~ 489
½Å´ÙÇý, ±è¿ëÀç, ¾ç½ÂºÎ, ÀÌÀç¸í, ÀÌ¿õÈñ, ±¸µ¿¾ï,
¼Ò¼Ó »ó¼¼Á¤º¸
½Å´ÙÇý ( Shin Da-Hye ) 
Soonchunhyang University Seoul Hospital Department of Radiology

±è¿ëÀç ( Kim Yong-Jae ) 
Soonchunhyang University Seoul Hospital Department of Radiology
¾ç½ÂºÎ ( Yang Seung-Boo ) 
Soonchunhyang Gumi Hospital Department of Radiology
ÀÌÀç¸í ( Lee Jae-Myeong ) 
Soonchunhyang University Bucheon Hospital Department of Radiology
ÀÌ¿õÈñ ( Lee Woong-Hee ) 
Soonchunhyang University Cheonan Hospital Department of Radiology
±¸µ¿¾ï ( Goo Dong-Erk ) 
Soonchunhyang University Seoul Hospital Department of Radiology

Abstract


Purpose: To evaluate effectiveness of percutaneous transluminal angioplasty (PTA) for transposed brachiobasilic arteriovenous fistula (tBBAVF), and to analyze the factors influencing patency after PTA.

Materials and Methods: In 101 patients who underwent operation for tBBAVF from January 2006 to February 2008, we identified 42 patients undergoing PTA. We conducted a retrospective analysis of sequential PTAs in these patients from 2006 to 2017.

Results: A total of 100 PTAs were performed. The technical success rate was 93% and the clinical success was 100%. Only ruptures occurred in 12% as minor complications. Primary patency rate was 61%, 29%, 7%, and secondary patency was 91%, 82%, 59% at 6, 12, and 24 months, respectively. Primary patency rate was lower in tBBAVF with rupture (p = 0.024). Secondary patency rate was significantly lower in the diabetes (p = 0.002).

Conclusion: Repetitive PTAs in tBBAVF are acceptable due to excellent secondary patency. Primary patency of tBBAVF is low in patients with rupture. Diabetes itself has a significant effect on secondary patency.

Å°¿öµå

Arteriovenous Fistula; Angioplasty; Vascular Patency; Diabetes Mellitus

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS